Cell and gene therapies have been grabbing news headlines, both for their potential to cure rare diseases and for their million-dollar price tags. Milliman pharmacists and healthcare experts explain why state Medicaid agencies are particularly affected and the strategies many are using for predicting uptake and covering these high costs. You can read the episode transcript on our <a href='https://www.milliman.com/en/insight/critical-point-episode-58-medicaid-cell-and-gene-therapies'>website</a>.

Cell and gene therapies have been grabbing news headlines, both for their potential to cure rare diseases and for their million-dollar price tags. Milliman pharmacists and healthcare experts explain why state Medicaid agencies are particularly affected and the strategies many are using for predicting uptake and covering these high costs. You can read the episode transcript on our website.

Cell and gene therapies have been grabbing news headlines, both for their potential to cure rare diseases and for their million-dollar price tags. Milliman pharmacists and healthcare experts explain why state Medicaid agencies are particularly affected and the strategies many are using for predicting uptake and covering these high costs.&nbsp;You can read the episode transcript on our <a href="https://www.milliman.com/en/insight/critical-point-episode-58-medicaid-cell-and-gene-therapies" rel="noopener noreferrer">website</a>.&nbsp;

How can Medicaid pay for cell and gene therapies?

Objectivity matters. Today, more than ever. With no agenda, other than getting it right, Milliman’s Critical Point podcast takes a deep dive into subject matter that affects the health and well-being of people across the globe, from healthcare to retirement security, flood insurance to autonomous vehicles. Through a team of professionals ranging from actuaries to clinicians, technology specialists to economists, Critical Point examines the inherent challenges – and innovative solutions – that Milliman consultants encounter through their daily work around healthcare, employee benefits, risk management, technology, investment consulting, insurance, and financial services.

Business

Technology

Objectivity matters. Today, more than ever. With no agenda, other than getting it right, Milliman’s Critical Point podcast takes a deep dive into subject matter that affects the health and well-being of people across the globe, from healthcare to retirement security, flood insurance to autonomous vehicles. Through a team of professionals ranging from actuaries to clinicians, technology specialists to economists, Critical Point examines the inherent challenges – and innovative solutions – that Milliman consultants encounter through their daily work around healthcare, employee benefits, risk management, technology, investment consulting, insurance, and financial services.

Share How can Medicaid pay for cell and gene therapies?

Sign up to save your podcasts

How can Medicaid pay for cell and gene therapies?

How can Medicaid pay for cell and gene therapies?

More shows like Critical Point

Freakonomics Radio

Planet Money

Economist Podcasts

WSJ What’s News

The Daily

Up First from NPR

KFF Health News' 'What the Health?'

McKinsey on Healthcare